[
  {
    "ts": null,
    "headline": "Big pharma's multiple looming patent cliffs: What to know",
    "summary": "The pharmaceutical industry is staring down a major patent cliff, with key drugs from Merck (MRK), Bristol Myers Squibb (BMY), and Johnson & Johnson (JNJ) set to lose exclusivity by 2030. Yahoo Finance Senior Reporter Anjalee Khemlani and Freedom Capital Markets chief global strategist Jay Woods join Market Domination host Josh Lipton to discuss the industry's risks and how Wall Street is responding. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=6c19949832175d329a0625c8a4547b90492148f57fabbb3a53416d99530dda68",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752267366,
      "headline": "Big pharma's multiple looming patent cliffs: What to know",
      "id": 135885558,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The pharmaceutical industry is staring down a major patent cliff, with key drugs from Merck (MRK), Bristol Myers Squibb (BMY), and Johnson & Johnson (JNJ) set to lose exclusivity by 2030. Yahoo Finance Senior Reporter Anjalee Khemlani and Freedom Capital Markets chief global strategist Jay Woods join Market Domination host Josh Lipton to discuss the industry's risks and how Wall Street is responding. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=6c19949832175d329a0625c8a4547b90492148f57fabbb3a53416d99530dda68"
    }
  },
  {
    "ts": null,
    "headline": "Top Analyst Reports for Microsoft, Alibaba & Merck",
    "summary": "MSFT, BABA, and MRK lead today's top analyst picks, with AI, e-commerce, and cancer drug strategies in sharp focus.",
    "url": "https://finnhub.io/api/news?id=7bed4b5f6c54cbfeb33d8ebb7515b8e06cd1110f04fadc3e747fa172aa8e4239",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752267360,
      "headline": "Top Analyst Reports for Microsoft, Alibaba & Merck",
      "id": 135885924,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MSFT, BABA, and MRK lead today's top analyst picks, with AI, e-commerce, and cancer drug strategies in sharp focus.",
      "url": "https://finnhub.io/api/news?id=7bed4b5f6c54cbfeb33d8ebb7515b8e06cd1110f04fadc3e747fa172aa8e4239"
    }
  },
  {
    "ts": null,
    "headline": "FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill",
    "summary": "MRK's regulatory filing for once-daily HIV pill DOR/ISL gets FDA acceptance, with a decision expected by April 2026.",
    "url": "https://finnhub.io/api/news?id=c1aa1a7dc266c7f6c8a7c5e477c30b713af9e0e13fdd5e86b41668621a959ed2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752250320,
      "headline": "FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill",
      "id": 135883599,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MRK's regulatory filing for once-daily HIV pill DOR/ISL gets FDA acceptance, with a decision expected by April 2026.",
      "url": "https://finnhub.io/api/news?id=c1aa1a7dc266c7f6c8a7c5e477c30b713af9e0e13fdd5e86b41668621a959ed2"
    }
  },
  {
    "ts": null,
    "headline": "MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success",
    "summary": "Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.",
    "url": "https://finnhub.io/api/news?id=b5f64f2411fc1e7a34cb0ea7518bd5f3bfd327bcee8a17322c5b362c90c3377d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752244860,
      "headline": "MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success",
      "id": 135883600,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.",
      "url": "https://finnhub.io/api/news?id=b5f64f2411fc1e7a34cb0ea7518bd5f3bfd327bcee8a17322c5b362c90c3377d"
    }
  },
  {
    "ts": null,
    "headline": "Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?",
    "summary": "MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.",
    "url": "https://finnhub.io/api/news?id=5127caba71b0fd88df71d7c0f5cb419c7d8d3797a90fdbd4a5f328ad054d5f91",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752236340,
      "headline": "Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?",
      "id": 135883601,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.",
      "url": "https://finnhub.io/api/news?id=5127caba71b0fd88df71d7c0f5cb419c7d8d3797a90fdbd4a5f328ad054d5f91"
    }
  },
  {
    "ts": null,
    "headline": "With Verona deal, Merck wagers on strength of lung drug’s patents",
    "summary": "The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make good on the deal, other secondary patents will need to hold up.",
    "url": "https://finnhub.io/api/news?id=e7a3feebbbfd79f195b0b38c09ca5ede336530300bd38c570cca5e2b1a5381d1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752232500,
      "headline": "With Verona deal, Merck wagers on strength of lung drug’s patents",
      "id": 135883602,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make good on the deal, other secondary patents will need to hold up.",
      "url": "https://finnhub.io/api/news?id=e7a3feebbbfd79f195b0b38c09ca5ede336530300bd38c570cca5e2b1a5381d1"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Jefferies raises TP after Verona acquisition",
    "summary": "Jefferies has raised its target price for Merck shares from $138 to $141, while maintaining its buy recommendation on them, after it announced the acquisition of Verona for approximately $10bn.The...",
    "url": "https://finnhub.io/api/news?id=efea4ee77d0a72e41d616cf60bbba9dda7730e9daec631396d43ad1fb7a46fc7",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752229634,
      "headline": "Merck: Jefferies raises TP after Verona acquisition",
      "id": 135879165,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Jefferies has raised its target price for Merck shares from $138 to $141, while maintaining its buy recommendation on them, after it announced the acquisition of Verona for approximately $10bn.The...",
      "url": "https://finnhub.io/api/news?id=efea4ee77d0a72e41d616cf60bbba9dda7730e9daec631396d43ad1fb7a46fc7"
    }
  },
  {
    "ts": null,
    "headline": "2 Top Stocks Down 16% and 17% This Year to Buy and Hold",
    "summary": "Merck and Bristol Myers Squibb are facing challenges due to recent (and future) patent cliffs.  Here are two great examples to consider: Merck (NYSE: MRK) and Bristol Myers Squibb (NYSE: BMY).  Merck is fast approaching the loss of patent exclusivity for Keytruda, its biggest growth driver by far.",
    "url": "https://finnhub.io/api/news?id=afbd329b7a05e5036a80cf0b264fa1ee1f28a845edaf921f67c1abd727729334",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752226560,
      "headline": "2 Top Stocks Down 16% and 17% This Year to Buy and Hold",
      "id": 135876740,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck and Bristol Myers Squibb are facing challenges due to recent (and future) patent cliffs.  Here are two great examples to consider: Merck (NYSE: MRK) and Bristol Myers Squibb (NYSE: BMY).  Merck is fast approaching the loss of patent exclusivity for Keytruda, its biggest growth driver by far.",
      "url": "https://finnhub.io/api/news?id=afbd329b7a05e5036a80cf0b264fa1ee1f28a845edaf921f67c1abd727729334"
    }
  },
  {
    "ts": null,
    "headline": "Merck: FDA approval for Bravecto Quantum",
    "summary": "Merck Animal Health announces that the US FDA has approved Bravecto Quantum , a new annual injectable treatment to protect dogs against fleas and ticks. This product will be available in veterinary...",
    "url": "https://finnhub.io/api/news?id=4196509e2db3a0866a047d03eed375a25c56df708dc072ff122a456a38141b3b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752211778,
      "headline": "Merck: FDA approval for Bravecto Quantum",
      "id": 135872308,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck Animal Health announces that the US FDA has approved Bravecto Quantum , a new annual injectable treatment to protect dogs against fleas and ticks. This product will be available in veterinary...",
      "url": "https://finnhub.io/api/news?id=4196509e2db3a0866a047d03eed375a25c56df708dc072ff122a456a38141b3b"
    }
  },
  {
    "ts": null,
    "headline": "Merck: seeks FDA approval for new HIV treatment",
    "summary": "Merck announces that the US FDA has agreed to review the New Drug Application for DOR/ISL, an experimental oral, once-daily, two-drug treatment for adults living with HIV-1 whose viral load is...",
    "url": "https://finnhub.io/api/news?id=dc9feae716aa8df762a19b5d0a0f5c3be71510d51db273da33e7ea5599cf068d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752210530,
      "headline": "Merck: seeks FDA approval for new HIV treatment",
      "id": 135871893,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announces that the US FDA has agreed to review the New Drug Application for DOR/ISL, an experimental oral, once-daily, two-drug treatment for adults living with HIV-1 whose viral load is...",
      "url": "https://finnhub.io/api/news?id=dc9feae716aa8df762a19b5d0a0f5c3be71510d51db273da33e7ea5599cf068d"
    }
  }
]